The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN) for potential breaches of fiduciary duty on the part of its directors and management.

The investigation focuses on determining if the Enfusion board breached its fiduciary duties to shareholders. Enfusion announced on January 13, 2025, that it would be acquired by Clearwater Analytics in a cash and stock deal worth $1.5 billion.

If you are a shareholder, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250113750877/en/